Effects of Percutaneous Transluminal Renal Angioplasty of Atherosclerotic Renal Artery Stenosis in High-Risk Patients.

Heart Failure Clinical Trial

— DAN-PTRAII  

Official title:

Effects of Percutaneous Transluminal Renal Angioplasty of Atherosclerotic Renal Artery Stenosis in High-Risk Patients - a Danish Nationwide Randomized Sham-Controlled Study.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05834803
• Other study ID #: DAN-PTRAII
• Status: Recruiting
• Phase: N/A
• Start date: June 26, 2023
• Est. completion date: June 1, 2027

Study information

• Verified date: May 2024
• Source: University of Aarhus
• Contact: Sebastian Nielsen, MD
• Phone: +45 40460321
• Email: sebane[@]rm.dk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to document a beneficial effect of percutaneous transluminal renal angioplasty (PTRA) of atherosclerotic renal artery stenosis in high-risk patients selected according to the criteria used in the DAN-PTRA study. The main questions the trial aims to answer are if renal artery stenting compared with optimal medical treatment alone has beneficial effects on: - Blood pressure - Kidney function - Hospitalizations for heart failure

Description:

Even with optimal medical care, patients with renovascular disease have a very high risk of cardiovascular events and an expected poor outcome. One treatment option of atherosclerotic renal artery stenosis is percutaneous transluminal renal angioplasty with stent placement. Renal artery stenting is, however, still a subject of debate as randomized trials have failed to show a benefit of this compared with optimal medical treatment alone. Following the results of the large CORAL trial in 2014, we established the national prospective DAN-PTRA study using strict and well-defined criteria to select patients for renal artery stenting. In this study, we observed a reduction in blood pressure, an improved kidney function, and a decrease in new hospital admissions due to heart failure after renal artery stenting. The DAN-PTRAII study is a nationwide high-quality randomized, sham-controlled clinical trial in patients with severe renovascular disease due to atherosclerotic renal artery stenosis. Only patients who fulfill the inclusion criteria on optimal medical treatment can enter the study and only the operator and his team will know whether the patients receive renal artery stenting or sham treatment. Participants will be followed closely for 6 months after the treatment to evaluate the effects of renal artery stenting compared with optimal medical treatment alone on blood pressure, kidney function and hospitalizations due to heart failure.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: June 1, 2027
• Est. primary completion date: June 1, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. One or more severe atherosclerotic renal artery stenoses defined as a stenosis =70% by catheter-based angiography.

2. In addition, at least one of the following high-risk clinical syndromes:

1. Resistant hypertension with average 24-hour ambulatory systolic blood pressure =150 mmHg despite =3 antihypertensive drugs including a diuretic, if tolerated, and each prescribed at optimal doses.

2. Rapidly declining kidney function with a reduction in estimated GFR of >5 mL/min per 1.73m2 per year and average 24-hour ambulatory systolic blood pressure =140 mmHg despite =3 antihypertensive drugs including a diuretic, if tolerated, and each prescribed at optimal doses.

3. Hospital admissions with acute decompensated heart failure (=2 hospitalizations for heart failure or =1 hospitalizations for sudden, "flash" pulmonary edema) with no obvious explanations such as nonadherence, left ventricular ejection fraction <40%, or valvular heart disease and average 24-hour ambulatory systolic blood pressure =140 mmHg despite =3 antihypertensive drugs including a diuretic, if tolerated, and each prescribed at optimal doses. All 24-hour ambulatory blood pressure monitorings are performed after nurse-administered medication.

Exclusion Criteria:

• Unable to provide informed consent.
• Treatment resistant heart failure episodes presumed caused by renovascular disease.
• Rapidly declining kidney function/acute kidney failure approaching the need for dialysis presumed caused by renovascular disease.
• Fibromuscular dysplasia or other non-atherosclerotic renal artery stenosis known to be present prior to randomization.
• Pregnancy or unknown pregnancy status in female of childbearing potential.
• Kidney size <7 cm (pole to pole length) supplied by target vessel.
• Previous kidney transplant.
• Previous PTRA treatment.
• Presence of a renal artery stenosis not amenable for treatment with a stent. Patients who are not eligible for randomization but treated with renal artery stenting outside the protocol are followed according to the DAN-PTRAII protocol in order to account for all PTRA treatments performed in Denmark in the study period. Patients treated with renal artery stenting without randomization in the study period

include patients with:

1. Treatment resistant heart failure episodes presumed caused by renovascular disease.

2. Rapidly declining kidney function/acute kidney failure approaching the need for dialysis presumed caused by renovascular disease.

3. At least one of the listed high-risk clinical syndromes AND one or more significant atherosclerotic renal artery stenoses defined as a stenosis of 50-69% by

catheter-based angiography with:

• a mean translesional gradient of =10 mm Hg, or
• a systolic translesional gradient of =20 mm Hg, or
• a renal fractional flow reserve (Pd/Pa) of =0.8

Related Conditions & MeSH terms

• Constriction, Pathologic
• Heart Failure
• Hypertension
• Hypertension, Renovascular
• Percutaneous Transluminal Angioplasty
• Renal Artery Obstruction
• Renovascular Hypertension

Intervention

Procedure:
• Renal artery stenting
Optimal medical therapy and percutaneous transluminal renal angioplasty with stent placement.
• Sham treatment
Optimal medical therapy and sham treatment.

Locations

Country	Name	City	State
Denmark	Aarhus University Hospital	Aarhus N
Denmark	Rigshospitalet	Copenhagen
Denmark	Odense University Hospital	Odense C

Sponsors (7)

Lead Sponsor	Collaborator
University of Aarhus	Aarhus University Hospital, Amsterdam UMC, Odense University Hospital, Rigshospitalet, Denmark, The Augustinus Foundation, Denmark., The Novo Nordic Foundation

Country where clinical trial is conducted

Denmark, 

References & Publications (1)

Reinhard M, Schousboe K, Andersen UB, Buus NH, Rantanen JM, Bech JN, Mafi HM, Langfeldt S, Bharadwaz A, Horlyck A, Jensen MK, Jeppesen J, Olsen MH, Jacobsen IA, Bibby BM, Christensen KL. Renal Artery Stenting in Consecutive High-Risk Patients With Atheros — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in 24-hour ambulatory systolic blood pressure.	Changes in 24-hour ambulatory systolic blood pressure from baseline to 6 months after renal artery stenting compared with optimal medical treatment alone in patients with 24-hour ambulatory average systolic blood pressure =150 mmHg at baseline.	6 months after PTRA/sham
Secondary	Changes in kidney function.	Changes in kidney function (estimated glomerular filtration rate) from baseline to 6 months after renal artery stenting compared with optimal medical treatment alone.	6 months after PTRA/sham
Secondary	Changes in antihypertensive treatment (defined daily doses).	Changes in antihypertensive treatment (defined daily doses) from baseline to 6 months after renal artery stenting compared with optimal medical treatment alone.	6 months after PTRA/sham
Secondary	Changes in 24-hour ambulatory systolic blood pressure (statistically adjusted for treatment changes).	Changes in 24-hour ambulatory systolic blood pressure from baseline to 6 months after renal artery stenting compared with optimal medical treatment alone in patients with 24-hour ambulatory average systolic blood pressure =150 mmHg at baseline. Changes in systolic blood pressure will be adjusted for changes in the defined daily doses (DDD) of antihypertensive medications, where a change of 1DDD equals a change of 5 mmHg in the systolic blood pressure.	6 months after PTRA/sham
Secondary	Number of participants with cardiovascular and kidney outcomes.	Clinical events included in the composite end point from baseline to 6-month follow-up: death from cardiovascular causes; death from renal causes; stroke; myocardial infarction; hospitalization for congestive heart failure; progressive renal insufficiency (a reduction from baseline of 50% or more in estimated GFR); permanent renal-replacement therapy; Clinical events are defined using the same criteria as in the Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) study except for progressive renal insufficiency (in the CORAL study defined as a reduction from baseline of 30% or more in the estimated GFR).; Only the first event per participant is included in the composite.	6 months after PTRA/sham
Secondary	Number of deaths from any cause.	Death from any cause from baseline to 6 months after renal artery stenting compared with optimal medical treatment alone.	6 months after PTRA/sham
Secondary	Health status on 12-Item Short Form Survey (SF-12).	Changes in 12-item short form health survey (SF-12) from baseline to 6 months after renal artery stenting compared with optimal medical treatment alone.; Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning.	6 months after PTRA/sham
Secondary	Number of participants with procedure-related major adverse events (MAE) <30 days of PTRA/sham.	Number of participants with procedure-related MAEs including: all cause mortality; rupture, dissection, perforation or occlusion of renal artery; critical bleeding (need of blood transfusion); embolization; significant loss of kidney function (reduction from baseline of 50% or more in eGFR); permanent renal-replacement therapy; ipsilateral nephrectomy; access complications requiring treatment: bleeding, pseudoaneurysm or thrombosis; stent thrombosis after renal artery stenting	<30 days after PTRA/sham